Merck’s investigational antibody MK-2214 has received fast-track designation from the FDA for the treatment of Alzheimer’s disease. MK-2214 targets phosphorylated serine 413 tau (pS413), a marker of ...
Did you know weak leg muscles accelerate cognitive decline & dementia risk after 40? Learn how to strengthen legs for better ...
Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...
Semaglutide, the drug behind weight-loss jabs Ozempic and Wegovy, does not slow cognitive decline among people with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback